History of thymoma and yellow fever vaccination [2]

Lancet

Volumn 364, Issue 9438, 2004, Pages 936-

  Barwick, Rachel ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LIVE VACCINE; YELLOW FEVER VACCINE;

ANAMNESIS; B LYMPHOCYTE; CELL COUNT; CELL FUNCTION; DIGEORGE SYNDROME; EXPERIMENTAL MODEL; HUMAN; HYPERTHYROIDISM; HYPOGAMMAGLOBULINEMIA; INCIDENCE; LETTER; MYASTHENIA GRAVIS; PRIORITY JOURNAL; RISK FACTOR; SIDE EFFECT; SURVIVAL; T LYMPHOCYTE; THYMECTOMY; THYMOMA; THYMUS HYPERPLASIA; TRAVEL; YELLOW FEVER;

EID: 4444359788     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17017-7     Document Type: Letter

References (5)

1. Barwick RS, Marfin AA, Cetron MS. Yellow fever vaccine-associated disease. Scheld WM, Murray BE, Hughes JM. Emerging infections. 6th edn :2004;25-34 ASM Press, Washington
2. Kitchener S. Viscerotropic and neurotropic disease following vaccination with the yellow fever 17D vaccine ARILVAX. Vaccine. 22:2004;2103-2105
3. Kelleher P, Misbah SA. What is Good's Syndrome: immunologic abnormalities in patients with thymoma. J Clin Path. 56:2003;12-16
4. Hirsch MS, Murphy FA. Effects of anti-thymocyte serum on 17-D yellow fever infection in adult mice. Nature. 216:1967;179-180
5. Perez EE, Bokszczanin A, McDonald-McGinn D, Zackai EH, Sullivan KE. Safety of live viral vaccines in patients with chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Pediatrics. 112:2003;e325